Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07895277). This is a study registration, not published results. Lead sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 6000 participants (ESTIMATED). Conditions: Pulmonary Nodules, Lung Neoplasms. Interventions: DEVICE: AI-Assisted Longitudinal CT Assessment and Pulmonary Nodule Management. Primary outcome measures: Lung Resection Yielding Benign Pathology Within 24 Months , Randomization through month 24. Procedures performed in this window are included even if their final pathology report is completed shortly afterward.. Brief summary: Patients with indeterminate lung nodules often face a choice between continued CT surveillance and invasive investigation. This trial compares management with or without access to an AI report that matches nodules across real serial CT scans, measures change, and estimates validated malignancy or invasiveness risks. The principal question is whether offering the report reduces lung resections that yield benign pathology over 24 months. Diagnostic delay, cancer stage, treatment opportunity, complications, and longer-term cancer outcomes are also assessed.